0001179110-14-003976.txt : 20140228 0001179110-14-003976.hdr.sgml : 20140228 20140228174042 ACCESSION NUMBER: 0001179110-14-003976 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140227 FILED AS OF DATE: 20140228 DATE AS OF CHANGE: 20140228 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Caffe Steven CENTRAL INDEX KEY: 0001579954 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 14657094 MAIL ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 edgar.xml FORM 4 - X0306 4 2014-02-27 0 0000792977 AMAG PHARMACEUTICALS INC. AMAG 0001579954 Caffe Steven 1100 WINTER STREET WALTHAM MA 02451 0 1 0 0 SVP, Ch. Dev. and Reg. Officer Common Stock 2014-02-27 4 A 0 4400 A 39400 D Stock Option (Right to Buy) 21.13 2014-02-27 4 A 0 26300 A 2024-02-27 Common Stock 26300 26300 D Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (the "Plan") that vests over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal annual installments over the next three years thereafter. Not applicable. Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% vesting on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Nancy R. Smith, attorney-in-fact for Reporting Person 2014-02-28